Mytelka DS, Lorenzo M, Stafkey-Mailey D, D’yachkova Y, Nagar S, Candrilli SD, Kaye JA. Real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma receiving systemic therapy in the United Kingdom. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A751.

OBJECTIVE: To describe real-world treatment patterns and outcomes (e.g. survival; health care resource use [HCRU]) in the United Kingdom (UK) for patients with advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy.

METHODS: UK-based physicians completed a web-based medical record abstraction for patients ≥18 years old with a diagnosis of advanced STS (other than Kaposi's sarcoma or gastrointestinal stromal tumors) from 1/1/2005 to 2/7/2014 who received ≥1 line(s) of systemic therapy for this cancer. Clinical characteristics, treatments, vital status, and HCRU were recorded.

RESULTS: Twenty-one physicians provided data for 199 patients. Patients' mean age at advanced STS diagnosis was 56.5 (±12.4) years, and 63% were male. Most common histologic subtypes were leiomyosarcoma (31%), rhabdomyosarcoma (17%), and fibroblastic sarcoma (12%). 38% of patients had >1 line and 6% had >2 lines of therapy, with the most common drugs across lines of therapy being doxorubicin (75%), ifosfamide (35%), gemcitabine (25%) and docetaxel (23%). Median survival estimates from start of first- and second-line therapy were 19 and 14 months, respectively. Across regimens, mean (SD) drug, administration, and treatment-related adverse event costs (in 2015 British Pound Sterling) for first-line therapy were £5,998 (£8,293), £3,201 (£2,146), and £272 (£1,056), and from second-line therapy onward (until death or end of follow-up; n=75) were £13,949 (£14,490), £3,703 (£2,437), and £637 (£1,918), respectively. From third-line therapy onward (n=11), these costs were £21,120 (£21,423), £3,959 (£2,906), and £755 (£2,503), respectively. Finally, the mean (SD) cost of all other health care services (medical and supportive care) was £1,050 (£3,252) after discontinuation of first-line therapy and £889 (£2,832) after discontinuation of second-line therapy.

CONCLUSIONS: This retrospective medical record abstraction provides real-world data on outcomes associated with treatment of advanced STS in the UK. Improving survival and reducing the economic burden of patients with advanced STS remain critical unmet needs.

Share on: